Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

← catalyst calendar

NCT07333742

Sponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
50actual
Sites
1
Country
South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-09-29actualWhen the study began enrolling
Primary completion2025-11-27actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-11-27actualThe whole study's end, after follow-up
First posted2026-01-12actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-01-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Fed Conditions
  • Healthy Volunteer

Interventions

  • Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
  • Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg

Primary outcomes

what the primary-completion date above is the date OF
The plasma concentration of gemigliptin, dapagliflozin, and metformin
measured - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration
The plasma concentration of gemigliptin, dapagliflozin, and metformin
measured - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed